García-Quintanilla, MeritxellCaro-Vega, José MPulido, Marina RMoreno-Martínez, PatriciaPachón, JerónimoMcConnell, Michael J2023-01-252023-01-252016-07-22http://hdl.handle.net/10668/10157LpxC inhibitors have generally shown poor in vitro activity against Acinetobacter baumannii We show that the LpxC inhibitor PF-5081090 inhibits lipid A biosynthesis, as determined by silver staining and measurements of endotoxin levels, and significantly increases cell permeability. The presence of PF-5081090 at 32 mg/liter increased susceptibility to rifampin, vancomycin, azithromycin, imipenem, and amikacin but had no effect on susceptibility to ciprofloxacin and tigecycline. Potentiating existing antibiotics with LpxC inhibitors may represent an alternative treatment strategy for multidrug-resistant A. baumannii.enAcinetobacter InfectionsAcinetobacter baumanniiAmidohydrolasesAmikacinAnti-Bacterial AgentsAzithromycinBacterial ProteinsCarbapenemsDrug Resistance, Multiple, BacterialImipenemMicrobial Sensitivity TestsMinocyclineRifampinTigecyclineVancomycinresearch article27270288open access10.1128/AAC.00407-161098-6596PMC4958213https://europepmc.org/articles/pmc4958213?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958213/pdf